Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

In two double-blind trials in 757 adults with severe hypertriglyceridemia, plozasiran lowered fasting triglycerides by 79% and 81% at month 12 and reduced acute pancreatitis rates.

• Why it matters: Severe hypertriglyceridemia is linked to higher acute pancreatitis risk, and lowering triglycerides may help mitigate that risk.
• What they did: Adults were randomized 2:1 to plozasiran 25 mg or placebo at baseline and months 3, 6, and 9; pooled adjudication assessed acute pancreatitis incidence and timing.
• The result: At 12 months, acute pancreatitis occurred at 1 per 100 patient-years with plozasiran versus 5 per 100 patient-years with placebo (rate ratio 0.22; P=0.008), alongside triglyceride targets <500 mg/dl in 91% and 93% versus 51% and 50%.

AI summary of the abstract · may contain errors · not medical advice · read the paper.